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a  b  s  t  r  a  c  t
Asthma  is  a chronic  inﬂammatory  disease.  Reticular  basement  membrane  (RBM)  thickening  is consid-
ered  feature  of airway  remodelling  (AR) particularly  in  severe  asthma  (SA).  Omalizumab,  mAb  to  IgE
is effective  in  SA  and  can  modulate  AR.  Herein  we  describe  protein  proﬁles  of  bronchial  biopsies  to
detect  biomarkers  of  anti-IgE  effects  on  AR  and  to explain  potential  mechanisms/pathways.  We  deﬁned
the  bronchial  biopsy  protein  proﬁles,  before  and  after  treatment.  Unsupervised  clustering  of  baseline
proteomes  resulted  in  very  good  agreement  with  the morphometric  analysis  of  AR.  Protein proﬁles  ofalectin-3
malizumab
roteomics analysis
nteractome
omalizumab  responders  (ORs)  were  signiﬁcantly  different  from  those  of  non-omalizumab  responders
(NORs).  The  major  differences  between  ORs  and  NORs lied  to smooth  muscle  and  extra  cellular  matrix
proteins.  Notably,  an IgE-binding  protein  (galectin-3)  was reliable,  stable  and  predictive  biomarker  of
AR  modulation.  Omalizumab  down-regulated  bronchial  smooth  muscle  proteins  in  SA.  These ﬁndings
suggest  that  omalizumab  may  exert  disease-modifying  effects on  remodelling  components.
©  2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Asthma is a chronic inﬂammatory disease of the airways char-
cterised by a variable narrowing of the airways. Asthma is a major
ealth problem worldwide that affects over 300 million patients
1]. Severe asthma affects a minority of the patients with this dis-
ase; however, most treatment resources are directed to these
atients [2]. Allergies are one of the most common and well-known
auses of asthma [3] Omalizumab, an anti-IgE monoclonal anti-
ody, has been approved for the treatment of “severe, uncontrolled
llergic asthma”, and its effectiveness has been conﬁrmed in several
ontrolled and real-life clinical trials [4–6].
∗ Corresponding author at: Allergy and Respiratory Diseases Unit, Dpt. of Internal
edicine, University of Genoa, IRCCS-IST AOU San Martino Pad. Maragliano L.go R.
enzi, 10 16132 Genoa, Italy. Tel.: +39 0105554890; fax: +39 0105556307.
E-mail addresses: canonica@unige.it, rina.miriello@unige.it (G.W. Canonica).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.imlet.2014.08.010
165-2478/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Personalised medicine [7] and targeted therapies are modern
methods of properly treating patients with the most cost-effective
approach [8]. There is an absolute need to pursue these approaches
and to make them feasible in the identiﬁcation of biomarkers of
clinical response [7].
In recent years, several biomarkers of clinical response have
been identiﬁed for severe asthma [9]. Among these, periostin is
particularly noteworthy, as high blood levels of periostin have
been demonstrated to be a reliable biomarker of clinical response
to some biotechnology-based treatments, such as lebrikizumab
[10] and omalizumab [11]. Reticular basement membrane (RBM)
thickening is considered a feature of airway remodelling [12] with
increasing prominence in severe asthma [13] with a deﬁned cut-off
value.
We recently published a report on the signiﬁcant effect of oma-
lizumab treatment on bronchial remodelling modulation after 12
months of treatment, which was determined by means of a his-
tological evaluation, according to ATS/ERS guidelines for its use
in severe corticosteroid refractory disease. Bronchial biopsies at
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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aseline and after therapy were analysed [14], and all patients were
ound to have clinically beneﬁted from the treatment. However,
egarding the modulation of airway remodelling, we surprisingly
dentiﬁed two groups: responders (i.e., reduction of RBM thick-
ning) and non-responders (i.e., increasing or stable RBM). No
orrelation of remodelling reduction with any clinical or functional
arameters was detected [14]. Although a relationship between
he smooth muscle bronchial component of remodelling and pul-
onary function reduction is known [15], evidence of any muscle
eduction upon omalizumab or indeed, any other treatment is lack-
ng.
To improve upon the previous study and in the context of the
eed to understand the molecular pathways in asthma and rela-
ionship to speciﬁc phenotypes [16], we further investigated the
ronchial specimens that were previously analysed, with the aim of
dentifying candidate biomarkers of response (in terms of bronchial
emodelling reduction). For this purpose, we  performed a pro-
eomic analysis of the specimens according to a strategy described
y Braido [8] and Wheelock [17]. In particular, we  used the multi-
imensional protein identiﬁcation technology (MudPIT) proteomic
pproach, a high-throughput methodology that allows the simul-
aneous identiﬁcation of hundreds/thousands of proteins from a
ingle complex sample [18], an evaluation of differential abundance
19,20], and a characterisation of the involved molecular pathways
21].
The protein proﬁles obtained from the MudPIT analysis
f bronchial biopsies were useful for identifying predictive
iomarkers and pathways of anti-IgE effects on remodelling and
nderstanding the potential mechanisms involved.
. Methods
.1. Subjects
Eight patients with severe, persistent atopic asthma (7 non-
mokers; 3 females; range age 40–62 years; mean age 47.0 ± 9.7;
ean body mass index (BMI) 23.8 ± 3.1; mean total plasma
gE 309.4 IU/l ± 218.2; mean FEV1 56.2% pred ± 14.5%; ACT score
1.1 ± 2.9) were enrolled in this study.
All the patients were treated with omalizumab according to the
IFA (Italian Drug Agency) prescription rules. The clinical features
f the patients were described in a previous report [14]. The study
as approved by the local ethics committee.
Two biopsies were obtained from each patient using a ﬂexible
ronchoscope (Pentax FB19-TX, Langley, UK) before and 12 months
fter omalizumab treatment. Bronchial biopsies were obtained
rom the right middle lobe.
.2. Morphometric analysis
The reticular basement membrane (RBM) thickness was mea-
ured by performing light microscopy image analysis of all the
iopsies before and after treatment according to the ERS/ATS rec-
mmendations [22] regarding lung structure, as described in a
revious study.
.3. Immunohistochemistry (IHC) and image analysis
Tissue specimens were ﬁxed in 10% formaldehyde at 4 ◦C for 4 h
nd were embedded in parafﬁn. The parafﬁn sections (3 m)  were
ewaxed, hydrated, and pretreated with an antigen-unmasking
olution for 30 min. The samples were then treated with blocking
olution (BLOXALL Blocking Solution, Vector Laboratories) to inac-
ivate endogenous peroxidases, pseudoperoxidases, and alkaline
hosphatase. The samples were then incubated for approximatelyetters 162 (2014) 2–10 3
10 min  in a working solution of blocking serum (normal goat
serum).
The sections were incubated overnight at 4 ◦C with a pri-
mary antibody (anti-human GAL-3 rat monoclonal antibody;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:50 in
phosphate-buffered saline (PBS). Subsequently, the sections were
incubated with a secondary antibody (biotinylated immunoglobu-
lin G diluted 1:200 in PBS) for 10 min. After several washes with
PBS, all the slides were incubated with a concentrated labelled
enzyme (biotin–streptavidin–peroxidase complex) for 5 min  at
room temperature. The peroxidase was developed with 0.04% 3,3-
diaminobenzidine in 50 mmol/L Tris–HCl buffer containing 0.03%
hydrogen peroxide for 10 min. After being rinsed with PBS, the
slides were counterstained with haematoxylin, coverslipped with
Eukitt, and examined by light microscopy.
The image analysis was  performed using the Leica Q500 MC
Image Analysis System (Leica, Cambridge, UK). For each biopsy
analysed, the optical density of the signals was quantiﬁed using
a computer. The video images were generated by a charge-coupled
device (CCD) camera (Leica) connected by a frame grabber to a
computer. Single images were digitised for image analysis at 256
grey levels. The imported data were quantitatively analysed using
Q500MC Software-Qwin (Leica). The tissue was selected by the
operator using the cursor, and the positive areas were automati-
cally estimated. A constant optical threshold and ﬁlter combination
was used. The signal quantisation was expressed as the percent
positive area in pixels per square micron [23].
2.4. Protein extraction, estimation, and tryptic digestion for
proteomic analysis
The dewaxed tissues (3-m-thick section from each sample)
were dried in a vacuum centrifuge and resuspended in 100 L
of 0.1 M NH4HCO3 pH 7.9 buffer with 10% acetonitrile. The tis-
sues were then homogenised and extracted by adding RapigestTM
SF reagent (Waters, Milford, MA,  USA) at a ﬁnal concentration
of 0.2% (w/v). The resulting suspensions were incubated under
stirring, ﬁrst at 100 ◦C for 20 min  and then at 80 ◦C for 2 h. Sub-
sequently, the protein concentration was  assayed using the SPNTM
Protein Assay Kit (G-Biosciences, Maryland Heights, MO,  USA), and
5 ± 0.5 g of protein from each sample was digested by adding
sequencing-grade modiﬁed trypsin (Promega, Madison, WI,  USA)
at an enzyme/substrate ratio of 1:50 (w/w) and incubating it
overnight at 37 ◦C. An additional 0.5 g aliquot of trypsin was added
the next morning, and the digestion continued for 4 h. The addition
of 0.5% triﬂuoroacetic acid (TFA) stopped the enzymatic reaction,
and a subsequent incubation at 37 ◦C for 30 min  completed the
RapiGest acidic hydrolysis [24]. The water-immiscible degradation
products were removed by centrifugation at 14,000 × g for 10 min.
The tryptic digest mixture was desalted using PepCleanTM C18 spin
columns (Pierce Biotechnology, Rockford, IL, USA) and was resus-
pended in 0.1% formic acid at a concentration of 0.4 g/L.
2.5. MudPIT analysis
The trypsin-digested samples were analysed using two-
dimensional microliquid chromatography coupled online with
tandem mass spectrometry (2DC-MS/MS, also referred to as Multi-
dimensional Protein Identiﬁcation Technology, MudPIT) (Thermo
Fisher, San José, CA, USA). Brieﬂy, 5 L of each digested peptide
mixture was ﬁrst loaded onto a strong cation exchange column
(Biobasic-SCX column, 0.32 i.d. × 100 mm,  5 m,  Thermo Fisher)
using a Micro AS autosampler (Thermo Fisher). The peptide mixture
was then eluted stepwise by applying an eleven-step ammonium
chloride concentration gradient (0, 10, 20, 30, 40, 80, 120, 200,
400, 600, and 700 mM).  Each salt step was directly loaded onto
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 reverse-phase C18 column (Biobasic-18, 0.180 i.d. × 100 mm,
 m,  Thermo Fisher) and separated with an acetonitrile gradient
eluent A, 0.1% formic acid in water; eluent B, 0.1% formic acid in
cetonitrile). The gradient proﬁle was started and maintained for
 min  with 5% eluent B, followed by 5–45% eluent B for 51 min,
5–80% eluent B for 5 min, and 95% eluent B for 9 min. The ﬂow
ate was 100 L/min, which was split to achieve a ﬁnal ﬂux of
 L/min. The peptides that were eluted from the C18 column were
irectly analysed with a hybrid linear ion trap mass spectrometer
LTQ-Orbitrap XL; Thermo Fischer) equipped with a nanospray
on source. The spray capillary voltage was set at 1.5 kV, and the
on transfer capillary temperature was maintained at 220 ◦C. For
ach step of the peptide elution from the C18 column, full mass
pectrometry (MS) spectra were recorded in the positive ion mode
ver a 400–1600 m/z range, with a resolving power of 60,000 (full
idth at half-maximum) and a scan rate of 2 spectra/s. This step
as followed by four low-resolution MS/MS  events that were
equentially generated in a data-dependent manner on the ﬁrst,
econd, third, and fourth most intense ions selected from the full
S spectrum, using dynamic exclusion for the MS/MS  analysis. In
articular, the MS/MS  scans were acquired by setting a normalised
ollision energy of 35% on the precursor ion and, when a peptide
on was analysed twice, applying an exclusion duration of 0.5 min.
.6. Database search
A computer analysis of the MS/MS  spectra was performed using
ioworks version 3.3.1, based on the SEQUEST algorithm (Univer-
ity of Washington, licensed to ThermoFinnigan Corp., San Jose,
A, USA). The experimental MS/MS  spectra were correlated with
he tryptic peptide sequences by comparisons with the theoreti-
al mass spectra, which were obtained by the in silico digestion of
 human protein database (approximately 226233 entries), down-
oaded in January 2012 from the National Center for Biotechnology
nformation (NCBI) website (www.ncbi.nlm.nih.gov). This analysis
nabled the identiﬁcation of peptide sequences and related pro-
eins. Because the conﬁdence of protein identiﬁcation depends on
he stringency of the identiﬁcation of the peptide sequence and
eptide matching, particularly when using data from a single pep-
ide, a high stringency was guaranteed using the following method.
he peptide mass search tolerance was set to 1.00 Da; the precursor
on tolerance was set to 50 ppm; and the intensity threshold was
et to 100. Moreover, searches were performed with no enzyme,
llowing mass measurement tolerance levels of 2.00 mass units for
eptides and 1.00 mass units for MS/MS  ions. To assign a ﬁnal score
o the proteins, the SEQUEST output data were ﬁltered by setting
he peptide probability to 1 × 10−3, the chosen minimum corre-
ation score values (Xcorr) were 1.5, 2.0, 2.5, and 3.0 for single-,
ouble-, triple-, and quadruple-charged ions, respectively and the
onsensus score to higher than 10. The false-positive peptide ratio,
alculated through a reverse database, was less than 3%.
The output data obtained from the SEQUEST software were com-
ared using an in-house algorithm, namely, the Multidimensional
lgorithm Protein Map  (MAProMa) [25].
.7. Spectral count normalisation and differential analysis
The protein lists were aligned using a speciﬁc MAProMa tool [25]
nd the average spectral count (SC) for each distinct protein was
alculated. Differences in the amount of analysed protein between
nalyses from the same tissue were balanced by normalising the
C values according to a method proposed by Carvalho et al. [26].
rieﬂy, the normalised SC (nSC) for each protein was calculated
y dividing the SC value of each protein (pSC) by the SC value sum
SC) of all the proteins belonging to the same list (nS = pSC/åSC).
n addition, only isoforms identiﬁed by the corresponding speciﬁcetters 162 (2014) 2–10
peptides were considered (or no redundant protein isoforms
were considered in the list). The omalizumab responder (OR) and
non-omalizumab responder (NOR) protein proﬁles obtained were
compared using the DAve and DCI algorithms in the MAProMa soft-
ware. DAve is an index of the relative ratio between two compared
protein lists, and DCI is an index used to evaluate the conﬁdence
of DAve. Taking into account the spectral count values, the most
signiﬁcant up-represented proteins in the non-responder proﬁle
exhibited a DAve ≥ +0.2 and a DCI ≥ +50; the most signiﬁcant down-
represented proteins exhibited a DAve ≤ −0.2 and a DCI ≤ −50.
2.8. Linear discriminant analysis
To perform the reduction of data dimensionality, the protein
lists obtained using the MudPIT replicate analysis method were
processed using linear discriminant analysis (LDA) [27]. This anal-
ysis was applied by using a common covariance matrix for all the
groups and the Mahalanobis distance [28] from each point to each
group’s multivariate mean. The identifying features (proteins) that
discriminated the analysed samples were considered to be those
with the largest F ratio (>4) and the smallest p-value (<0.05). Specif-
ically, the F ratio represented the model mean square divided by the
error mean square, whereas the p-value indicated the probability
of obtaining an F value greater than that calculated if, in reality,
there was no difference between the population group means.
2.9. Hierarchical clustering
The protein lists were handled and aligned using MAProMa
software [25]. Biological and technical replicates were evaluated
using an unsupervised learning method, such as hierarchical clus-
tering (HC) [29] using in-house R-scripts, which was based on the
XlsReadWrite, clue, and clValid libraries (http://cran.r-project.org).
In particular, the Euclidean distance metric was  applied, and an
agglomerative coefﬁcient was calculated.
2.10. Network analysis
A global Homo sapiens protein interactomic network with more
than 22,000 nodes and 200,000 interactions was built using the
Bionetbuilder Cytoscape plugin [30]. This network combines inter-
actome data sets from major public online repositories, including
HPRD, MINT, BioGrid, IntAct, DIP, BIND, KEGG, MPPI, and GO.
All types of interactions were retrieved from each repository
without applying a p-value threshold. Protein-DNA, protein-RNA,
protein-metabolite, and protein-drug interactions, if present in the
data sets, were removed, as were duplicates and self-interactions.
Starting from the list of experimentally identiﬁed proteins, the cor-
responding network was extracted. Proteins that were not mapped
or were mapped as isolated components were not considered in
the analysis. The network was analysed using Cytoscape software
[31]. In particular, the Bingo 2.44 plugin [32] was used to empha-
sise sub-networks based on functionally organised GO terms, and
the MCODE plugin [33] was  used to cluster sub-networks based on
their topology and, speciﬁcally, by considering densely connected
regions.
3. Results
Protein proﬁles of FFPE (formalin ﬁxed parafﬁn embedded) 16obtained before and 12 months after anti-IgE monoclonal antibody
(omalizumab) treatment. Each patient was  classiﬁed, based on a
morphometric analysis [14], as a omalizumab responder or a non-
omalizumab responder.
P. Mauri et al. / Immunology L
Fig. 1. 2-D virtual map, of FFPE bronchial biopsies proteome obtained plotting MW
versus pI of the identiﬁed proteins by MAProMa software. The protein lists are
reported in Supplementary Information Table 1. A colour/shape code is assigned to
e
f
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s
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p
Fach  protein according to its SEQUEST score value (yellow/triangle ≤ 15, blue/square
rom >15 to <35, red/circle ≥ 35). (a) Responder (OR), (b) non-responder (NOR).
.1. Protein proﬁles
The MudPIT proteomic approach allowed the identiﬁcation of
ver one hundred proteins from each sample. Using the MaProMa
oftware, each protein list from the OR and NOR patients was
utomatically plotted onto a 2-D map  according to the theoretical
olecular weight (MW)  and isoelectric point (pI) of the identiﬁed
roteins. A representative example is shown in Fig. 1, which shows
ig. 2. Venn diagram of differential proteins obtained comparing each other the four groetters 162 (2014) 2–10 5
the 2-D maps corresponding to all the identiﬁed proteins. In par-
ticular, it is interesting to note that we  were able to characterise a
signiﬁcant number of proteins with extreme theoretical MW val-
ues <10 kDa (such as mutant beta-globin, 2 kDa) and >200 kDa (such
as neuroblast differentiation-associated protein, AHNAK, 628 kDa),
along with proteins having a very acidic pI (<4), such as calmod-
ulin (pI = 3.9) or a very basic pI (>10), such as serine/arginine-rich
splicing factor 7 isoform 1 (pI = 12.3).
Overall, 1330 distinct proteins were identiﬁed, and a complete
list of the identiﬁed proteins is presented in Supplementary Table
1. To reduce the false-positive peptide identiﬁcation rate, stringent
ﬁltration criteria were applied. Of note, while the weight of the
biopsies was stable, the number of identiﬁed proteins in the OR
samples was always higher than that in the NOR samples; this ﬁnd-
ing suggested a wider qualitative distribution of proteins in the OR
patients.
Considering the 4 biopsy groups (omalizumab responder
baseline, ORb; omalizumab responder post-treatment, ORp; non-
omalizumab responder baseline, NORb; and non-omalizumab
responder post-treatment, NORp), it was observed that a higher
number of proteins changed in the OR compared with the NOR
due to the anti-IgE treatment. Speciﬁcally, 79 and 34 proteins
presented a different abundance level after the treatment in
ORs and NORs, respectively. In addition, a comparison of OR vs.
NOR, both at baseline (ORb vs NORb) and post-treatment (ORp
vs NORp), demonstrated a substantial difference with respect
to the number of proteins presenting a differential abundance
(Fig. 2).
These proteomic ﬁndings are in agreement with the morpho-
metric data, conﬁrming the omalizumab effect on ORs. This result
indicates that at baseline, ORs possess proteins that are potentially
susceptible to the treatment. For this reason we  investigated in
depth the differences between the ORs and NORs before treatment
by performing clustering and label-free differential analyses.
3.2. Clustering and descriptors
Protein lists from bronchial biopsies of each patient were com-
pared and used to perform an unsupervised clustering analysis.
The baseline ORs and NORs were segregated into the groups pre-
viously deﬁned by the morphometric analysis (Fig. 3). In this
context, 81 proteins were identiﬁed as descriptors based on a lin-
ear discriminant analysis (LDA) performed to discriminate between
the two  groups (discriminators are listed in Supplementary
Table 2).
ups (ORb, NORb, ORp and NORp), classiﬁed according morphometric analysis.
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aig. 3. Unsupervised hierarchical clustering of protein lists obtained by analyzin
b)  selected proteins. For each protein the heat map  shows the normalised spe
oefﬁcient > 0.8).
.3. Label-free differential analysis
A label-free approach, based on MaProMa algorithms [25], was
sed for evaluating, independently of the clustering analysis, dif-
erential abundance levels of proteins by comparing NORb versus
Rb samples. A total of 107 proteins were differentially abundant;
n particular, 23 and 84 proteins were up-regulated in the NORb
nd ORb biopsies, respectively (Supplementary Table 2). Of note,
he label-free procedure conﬁrmed 48 descriptor proteins (approx-
mately 60%) selected by LDA. In addition, another 10 descriptors
ere detected at a low level (DCI < 50), but they were present exclu-
ively in ORb; the remaining 23 (out of 81 descriptors) were present
n 3 out of 4 omalizumab responders as prevalent compared with
ORb..4. Network analysis
The identiﬁcation of a very large number of proteins and the
vailability of a H. sapiens network dataset constituted the premise biopsies of responder (ORb) and non-responder (NORb) patients. (a) Total and
count (SC) values. The obtained cluster resulted well structured (agglomerative
for investigating the functional relationships between groups iden-
tiﬁed in our proteomic analyses. In this context, the identiﬁed
proteins, including differentially expressed proteins, were plot-
ted onto the Global Mammalian Protein Interactomic network by
means of Cytoscape and its plug-ins (see Section 2). This procedure
allowed the mapping of 584 nodes (approximately 72% of the total
identiﬁed proteins/nodes), involving 4642 interactions, grouped
into 7 distinct main networks (Supplementary Fig. 1A–D), including
the following: (a) structural proteins (including cytoskeletal and
myosin/actin-related proteins, annexins, and keratins), (b) extra-
cellular matrix (ECM, including collagens) proteins, (c) metabolism
and redox regulation proteins, (d) heat shock proteins, (e) immune
system proteins, (f) 14-3-3-interacting proteins, and (g) genetic
information-processing proteins (including ribosomal proteins and
histones). Figs. 4 and 5 show the most interesting interactions
identiﬁed in the nodes/proteins plotted on the map. Speciﬁcally,
Fig. 4 shows the up- (in red) and down-regulated (in blue) proteins
in OR vs. NOR at baseline, as well as the identiﬁed and unregu-
lated proteins (in white). While Fig. 5 shows the up- (in red) and
P. Mauri et al. / Immunology Letters 162 (2014) 2–10 7
Fig. 4. Network involved the main responder (ORb) versus non-responder (NORb) differences. Red nodes = proteins up-regulated in ORb; blue nodes = proteins up-regulated
i ons; g
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nn  NORb; white nodes = unchanged proteins; grey edges = protein–protein interacti
own-regulated (in blue) proteins before and after treatment in the
esponder patients.
The major differences between the OR and NOR at baseline were
etected in the ECM, contractile and structural proteins, includ-
ng myosin- and actin-related proteins. Speciﬁcally, in the OR the
p-regulation of vimentin (VIM), COL1A1 and PDGFB fusion trans-
ripts (COL1A1), collagen alpha-2(I) chain (COL1a2), collagen (VI)
lpha-1 chain (COL6A1), type VI collagen alpha-2 chain precursor
COL6A2), collagen type VI alpha 3 chain (COL6A3), actin-like pro-
ein (ACT), actin, alpha skeletal muscle (ACTA1), actin, cytoplasmic
 (ACTB), alpha-actinin-1 isoform b (ACTN1), periostin (POSTN),
nd calmodulin 3 (CALM3) was detected; therefore, these proteins
ere deﬁned as predominant in the OR. Of note, periostin was
etected in all the OR biopsies and in two of the four NOR biopsies.
ig. 5. Network involved the main baseline (ORb) versus post-treatment (ORp) differ
odes  = proteins up-regulated in ORp; white nodes = unchanged proteins; grey edges = prreen edges = genetic interactions.
An IgE-binding protein (LGALS3, galectin-3, Gal-3), perlecan
(HSPG2), elastin (ELN), transforming growth factor-beta (TGFB1),
vinculin (VCL), ezrin (EZR), myosin 9 (MYH9), myosin light
polypeptide 6 (Myl6), myosin-11 (MYH11), actin, gamma-enteric
smooth muscle isoform 1 (ACTG2), ﬁbulin-5 (FBLN5), and ﬁbulin-
2 (FBLN2) were identiﬁed exclusively in the OR. Among these
groups (predominant and exclusive proteins), we analysed, by
immunochemistry, vimentin (up-regulated) and Gal-3 (exclusive)
in bronchial biopsies, conﬁrming the clear difference previously
detected by the MudPIT analysis (Fig. 6 and Supplementary Fig. 2).
The proteomic analysis of bronchial tissues after twelve months
of omalizumab treatment showed the following: (a) ECM and
structural proteins were globally decreased and (b) Gal-3 was
the most stable protein marker among the exclusive proteins. Of
ences in responder patients. Red nodes = proteins down-regulated in ORp; blue
otein–protein interactions; green edges = genetic interactions.
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ote, omalizumab treatment induced at 12 months a decrease in
uscle-associated components, such as calmodulin 3 (CALM3),
yosin light polypeptide 6 (MYL6), prelamin A/C (LMNA), myosin-
1 (MYH11), desmin (DES), tropomyosin alpha-1 (TPM1), vinculin
VCN), vimentin (VIM), actin, gamma-enteric smooth muscle iso-
orm 1 (ACTG2), actin alpha skeletal muscle (ACTA1), and transgelin
TAGLN), in the OR bronchial tissues (Fig. 5). In the NORs, the
bsence of these markers at baseline was conﬁrmed after 12
onths of omalizumab treatment. Also, few proteins, mainly ker-
tins, changed their abundance after treatement, according with
he stability of RBM.
. Discussion
In the present work, we investigated the protein proﬁles of biop-
ies from asthma patients using a MudPIT approach. Although the
elatively few samples and the identiﬁcation of moderately abun-
ant proteins (cytokines were not detected due to their very low
xpression levels), it is necessary to underline that the asthma
atients were carefully phenotyped by histological evaluation and
hat the proteomic description produced high-resolution and unbi-
sed results. However, due to the difﬁcult to obtain biopsies from
evere asthmatic patients, this work represents the larger set inves-
igated by proteomics analysis, as far as we know. Speciﬁcally, up to
ow it was not infered structural and molecular aspects in relation
o anti-IgE treatment.
The protein lists from the pre-treatment (baseline) patients
ere evaluated by hierarchical clustering, and the resulting seg-
egation was in very good agreement between the OR/NOR
roups, based on morphometric data from pre- and post-treatment
ith anti-IgE mAb  [14]. The majority of the baseline descriptors
ere conﬁrmed by an OR vs. NOR differential analysis. Shared
escriptors and differentially abundant proteins may  represent
iomarkers for predicting the remodelling response to anti-IgE
herapy.-responder (NORb) patients before anti-IgE treatment.
The major differences between ORs and NORs lied in the
cytoskeleton, mainly smooth muscle and ECM proteins. Smooth
muscle proteins, mainly myosins and actins, decreased after treat-
ment in the ORs, whereas this was  not the case in the NORs, in
whom the levels of these proteins at baseline were negligible. This
is the ﬁrst report of a reduction in the muscular component of
asthma remodelling due to a therapeutic intervention. The possible
relationship between this reduction and lung function parameters
should be further investigated in future studies.
ECM predominant proteins, such as vimentin (a marker of air-
way remodelling), periostin (a marker of clinical response), and
other proteins in this group were present in both OR and NOR biop-
sies; therefore, they are not OR-speciﬁc markers. In addition, they
were not stable after treatment (see Supplementary Table 2).
Regarding ECM proteins, Gal-3 was  the most stable biomarker
associated with the prediction of remodelling modulation. Gal-3
gene therapy determines the inhibition of asthmatic reactions [34]
and decreases airway remodelling in animals [35]. Also, Sanchez-
Cuellar et al. [36] reported that galectins play roles in the resolution
phase of inﬂammatory responses by promoting anti-inﬂammatory
effects. In addition, OVA allergen-induced investigations in Gal-3
KO mice demonstrated that Gal-3 is involved in airway inﬂamma-
tion by inﬂuencing the development of proﬁbrotic and angiogenic
mediators [37]. In particular, Gal-3 expression is related to alter-
native macrophage activation (AMA), while classical macrophage
activation with LPS reduces Gal-3 expression. In this context, our
ﬁndings indicate that, before treatment, non-omalizumab respon-
der (NOR) and omalizumab responder (OR) patients belong to
distinct sub-groups differentiated by the presence of Gal-3 in
bronchial tissue.
Gal-3 is part of a protein complex that includes IgE. Its main
receptors, Fc RI (a high-afﬁnity receptor for IgE) and CD23, are
where Gal-3 binds both IgE and FcRI [38]. Of note, Kim et al. [39]
reported that IgE–FcRI complexes dissociate extremely slowly and
cannot be disrupted by strictly competitive inhibitors. It may  be
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peculated that the presence of Gal-3 may  have a role in the dis-
uption of IgE–FcR1 interaction, facilitating the dissociation of this
omplex, and promoting the effectiveness of anti-IgE therapy for
emodelling in Gal-3-positive patients (OR).
In summary, Gal-3 is a regulatory molecule acting at various
tages from acute to chronic inﬂammation and tissue ﬁbrogene-
is [40]. In the initial phase of allergic induction, Gal-3 stimulates
nﬂammation through macrophage release and increased IgE pro-
uction, with the ﬁnal result being airway remodelling by collagen
nd ﬁbronectin deposition [41]. These data suggest a possible role
f Gal-3 in the omalizumab mechanism of action on remodelling,
hich further stresses the importance of detecting of Gal-3 as a
iomarker of treatment response.
. Concluding remarks
Our ﬁndings indicate the following: (a) the proteomes of anti-
gE mAb  OR patients are largely qualitatively and quantitatively
ifferent from those of NOR patients; (b) the proteomic state of
ronchial tissue before omalizumab treatment represents a selec-
ive pattern of anti-IgE response; (c) omalizumab down-regulates
ronchial smooth muscle proteins in subtype of severe asthmat-
cs; (d) a possible explanation of the biochemical basis of OR/NOR
utcomes of anti-IgE treatment, it may  be due to a role of Gal-3
n the distruption of IgE–FcRI interaction and (e) Gal-3 can be
onsidered a reliable biomarker with which to predict the modula-
ion of airway remodelling in severe asthma patients treated with
malizumab.
Because Gal-3 is a matrix protein, it is feasible to detect it in
erum or urine [42]. This ﬁnding could be of great interest for deﬁn-
ng the subgroup of candidate patients who are able to modulate
ronchial remodelling. Overall, these ﬁndings might suggest that
lockade of IgE with omalizumab is capable of exerting disease-
odifying effects on remodelling components of chronic disease.
lso, the reported approach may  be considered a proof of principle,
nd it promises to enhance the ability to type severe asthma and
o identify novel potential biomarkers by means of its application
n larger indipendent patient sets, possibly through a multicentre
ollaboration.
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